Advancing Migraine Research: HRHR’s Role in the Development of FDA-Approved Medication Emgality

The Ongoing Challenge of Migraine Headaches and the Need for Clinical Research

Migraine headaches are a debilitating neurological condition associated with intense, throbbing pain. Additional symptoms may include nausea, sensitivity to light or sound, and visual disturbances. Those who suffer from migraine headaches are at higher risk of developing depression, anxiety, and other mental health disorders. This connection may stem from factors such as stress, the impact on daily life, side effects from treatment, sleep disturbances, genetic predispositions, and other potential contributors.

Continued clinical research into how to prevent and treat migraine headaches is imperative and has been prioritized by many pharmaceutical and medical research organizations over the past two to three decades.

The Broader Picture: Why Migraine Research Matters

Migraine headaches can significantly affect an individual’s ability to function, both physically and mentally. As symptoms compound and the condition persists, the potential complications related to mental health and quality of life also grow. This highlights the importance of continued research that not only explores new treatment options but also considers the broader impact migraines have on individuals’ lives. Clinical studies remain an essential part of this work.

HRHR’s Role in Advancing Migraine Research Through Clinical Trials

In 2016, significant clinical research efforts in the United States were underway to develop new medications for the treatment and prevention of migraine headaches. At this time, Dr. Freeman and the HRHR team began researching a new therapy in the treatment and prevention of migraine headaches with the company Eli Lilly. HRHR worked on several different late-phase migraine clinical trials with Eli Lilly from 2016 to 2018, providing valuable data and participant outcomes that helped shape the final approval process.

On September 27, 2018, the FDA approved Eli Lilly’s investigational medication Glacanexumab as brand-name Emgality for the prevention of migraine headaches in adults.

About Emgality (Galcanezumab): The Outcome of Collaborative Research

Emgality (galcanezumab) is a medication approved by the FDA for the prevention of migraine headaches in adults. Developed by Eli Lilly, the drug underwent late-phase clinical trials between 2016 and 2018, in which HRHR played a key research role.

The HRHR team is privileged to have participated in bringing such an important medication to the public. The FDA approval of Emgality meant the offering of a new class or type of migraine prevention medication—what is referred to as “first-in-class.” Since its approval, thousands of individuals have used Emgality as part of their migraine prevention regimen.

Ongoing Efforts: HRHR’s Continued Work in Migraine Studies

HRHR’s commitment to migraine research did not end with the approval of Emgality. The team remains focused on advancing understanding and exploring new potential treatments for migraines and related conditions. Today, Dr. Freeman and the HRHR team continue to work in migraine research with the understanding that there is still more to discover in the field of migraine treatment. They are currently accepting patients for a migraine treatment study.

Participate in a Migraine Study: Help Advance Migraine Research

If you experience migraines and are interested in contributing to ongoing clinical research, you may be eligible to participate in HRHR’s current migraine study. By participating, you can help support the advancement of potential treatment options for people living with this challenging condition.